Authorized COVID Antiviral Fails to Cut Hospitalization Risk | MedPage Today
https://www.medpagetoday.com/infectiousdisease/covid19/101172?xid=nl_mpt_DHE_2022-10-15&eun=g148346d0r&utm_source=Sailthru&utm_medium=email&utm_campaign=Weekly%20Review%202022-10-15&utm_term=NL_DHE_Weekly_Active Molnupiravir failed to reduce the risk for hospitalization or death in high-risk COVID-19 outpatients who took the oral antiviral within 5 days of symptoms, a large open-label multicenter trial…